Frontiers in pharmacology · 2026
Efficacy and safety of jinlida granule in the treatment of diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yong Qi, Xu Yunxi, Zhang Peiying, Bai Hua, Xu Chao, Ye Hejiang
Аннотация
BACKGROUND: Diabetic kidney disease (DKD), a major microvascular complication of diabetes, represents the leading cause of end-stage renal disease globally. Jinlida Granule (JLD), a multi-botanical Traditional Chinese Medicine preparation, has shown potential in type 2 diabetes management; however, a comprehensive systematic evaluation of its efficacy and safety specifically for DKD is lacking.
OBJECTIVE: To systematically evaluate the efficacy and safety of JLD for DKD through a meta-analysis.
METHODS: We conducted a systematic search of Chinese and English databases and clinical trial registries for randomized controlled trials (RCTs) on JLD for DKD from inception to 9 October 2025. Two researchers independently performed literature screening, data extraction, and quality assessment using the Cochrane Risk of Bias (RoB) 2 tool. Meta-analysis was conducted with a random-effects model using STATA 15.0 and Review Manager 5.4. Subgroup and sensitivity analyses were performed.
RESULTS: Twelve RCTs involving 1,341 patients were included. JLD was associated with significant reductions in serum creatinine (MD -30.54 μmol/L, 95% CI -37.61 to -23.47; I2 = 94%), blood urea nitrogen (MD -0.95 mmol/L, 95% CI -1.29 to -0.60; I2 = 79%), urinary albumin excretion rate (MD -27.09 mg/24 h, 95% CI -29.16 to -25.02; I2 = 94%), and HbA1c (MD -0.86%, 95% CI -1.23% to -0.49%; I2 = 83%). Improvements were also observed in lipid profiles and inflammatory markers. Subgroup analyses suggested greater benefit in early-stage DKD and with specific combination regimens. Adverse events did not differ significantly between groups (RR 0.86, 95% CI 0.50-1.48). Substantial heterogeneity was noted.
CONCLUSION: Current evidence suggests that adjunctive JLD may provide multifaceted clinical benefits for DKD patients, with a comparable safety profile. However, these findings should be interpreted cautiously given the moderate to high risk of bias and considerable heterogeneity. Well-designed, large-scale RCTs are required.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251178318, identifier [CRD420251178318].
OBJECTIVE: To systematically evaluate the efficacy and safety of JLD for DKD through a meta-analysis.
METHODS: We conducted a systematic search of Chinese and English databases and clinical trial registries for randomized controlled trials (RCTs) on JLD for DKD from inception to 9 October 2025. Two researchers independently performed literature screening, data extraction, and quality assessment using the Cochrane Risk of Bias (RoB) 2 tool. Meta-analysis was conducted with a random-effects model using STATA 15.0 and Review Manager 5.4. Subgroup and sensitivity analyses were performed.
RESULTS: Twelve RCTs involving 1,341 patients were included. JLD was associated with significant reductions in serum creatinine (MD -30.54 μmol/L, 95% CI -37.61 to -23.47; I2 = 94%), blood urea nitrogen (MD -0.95 mmol/L, 95% CI -1.29 to -0.60; I2 = 79%), urinary albumin excretion rate (MD -27.09 mg/24 h, 95% CI -29.16 to -25.02; I2 = 94%), and HbA1c (MD -0.86%, 95% CI -1.23% to -0.49%; I2 = 83%). Improvements were also observed in lipid profiles and inflammatory markers. Subgroup analyses suggested greater benefit in early-stage DKD and with specific combination regimens. Adverse events did not differ significantly between groups (RR 0.86, 95% CI 0.50-1.48). Substantial heterogeneity was noted.
CONCLUSION: Current evidence suggests that adjunctive JLD may provide multifaceted clinical benefits for DKD patients, with a comparable safety profile. However, these findings should be interpreted cautiously given the moderate to high risk of bias and considerable heterogeneity. Well-designed, large-scale RCTs are required.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251178318, identifier [CRD420251178318].